Tail vein transplantation of human umbilical cord blood mesenchymal stem cells for treatment of dilated cardiomyopathy

doi:10.3969/j.issn.2095-4344.2013.06.014

Abstract

Abstract:

BACKGROUND: In vitro studies have demonstrated that human umbilical cord blood mesenchymal stem cells can differentiate into autorhythmic myocardial cells. Few studies are reported regarding tail vein transplantation of human umbilical cord blood mesenchymal stem cells for treatment of dilated cardiomyopathy.
OBJECTIVE: To investigate the influences of tail vein transplantation of human umbilical cord blood mesenchymal stem cells on myocardial structure and heart function in a rat model of dilated cardiomyopathy.
METHODS: Dilated cardiomyopathy was induced in Wistar rats by intraperitoneal injection of adriamycin. In the dilated cardiomyopathy group, human umbilical cord blood mesenchymal stem cells were injected into the rats via the tail vein at 8 weeks after dilated cardiomyopathy induction. In the model control group, equal amounts of DMEM were identically injected. In the blank control group, the rats were not subjected to dilated cardiomyopathy induction, but the same amount of physiological saline was injected at the same time point.
RESULTS AND CONCLUSION: Compared with the blank control group, the heart function of rats in the dilated cardiomyopathy group and model control group was significantly injured, and the disease severity was milder in the dilated cardiomyopathy group than in the model control group. Troponin T expression was detected in the cells of rats receiving tail transplantation of human umbilical cord blood mesenchymal stem cells. These findings suggest that human umbilical cord blood mesenchymal stem cells can promote the recovery of heart function and alleviate the lesion of myocardial tissue in rats with dilated cardiomyopathy.

CLC Number:

R394.2

Luo Jian-hong, He Xue-hua, Liao Jin-mao, Yuan Yong-hua, Hu Sha-ya. Tail vein transplantation of human umbilical cord blood mesenchymal stem cells for treatment of dilated cardiomyopathy[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(6): 1029-1036.

Figures/Tables 12

References

[1] Strauer BE, Brehm M, Zeus T,et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans.Circulation. 2002; 106(15):1913-1918.

[2] Wang C,Xu Y,Song WG,et al.Xibao yu Fenzi Mianyixue Zazhi. 2007;23(5):466-468. 王超,徐蕴,宋文刚,等.大鼠骨髓间充质干细胞分离培养方法的建立及其表型分析[J].细胞与分子免疫学杂志,2007,23(5) : 466-468.

[3] Shah HR, Vaynblat M, Ramdev G,et al. Experimental cardiomyopathy as a model of chronic heart failure. J Invest Surg. 1997;10(6):387-396.

[4] NAKAHATAT, Expansion of hematoPoietic Progenitors．In: Bajus JL，et al．eds，Education Program of the 26th Congress of The Intemational Society of Haematolog Singa Pore. 1996: 29-302．

[5] Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000; 109(1):235-242.

[6] Kim JW, Kim SY, Park SY,et al. Mesenchymal progenitor cells in the human umbilical cord. Ann Hematol. 2004;83(12): 733-738.

[7] Goodwin HS, Bicknese AR, Chien SN, et al. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant. 2001;7(11):581-588.

[8] Kern S, Eichler H, Stoeve J,et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.Stem Cells. 2006;24(5):1294-1301.

[9] Chang YJ, Shih DT, Tseng CP,et al. Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. Stem Cells. 2006;24(3):679-685.

[10] Huang JL,Yang SX. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2008;12(47):9367-9370. 黄景玲,杨水祥.人脐血源性间充质干细胞向心肌细胞的诱导分化[J].中国组织工程研究与临床康复,2008,12(47):9367-9370.

[11] Leor J, Guetta E, Feinberg MS,et al. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells. 2006;24(3):772-780.

[12] Henning RJ, Abu-Ali H, Balis JU, et al. Human umbilical cord blood mononuclear cells for the treatment of acute myocardial infarction. Cell Transplant. 2004;13(7-8):729-739.

[13] Ma N, Ladilov Y, Moebius JM,et al. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells.Cardiovasc Res. 2006;71(1):158-169.

[14] Hu CH,Wu GF,Wang XQ,et al. Zhonghua Xinxueguanbing Zazhi. 2006;34(7):587-590. 胡承恒,伍贵富,王小庆,等.人脐血单个核细移植治疗大鼠急性心肌梗死的实验研究[J].中华心血管病杂志,2006,34(7):587-590.

[15] Sadat S, Gehmert S, Song YH,et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF.Biochem Biophys Res Commun. 2007;363(3):674-679.

[16] Siepe M, Akhyari P, Lichtenberg A,et al. Stem cells used for cardiovascular tissue engineering. Eur J Cardiothorac Surg. 2008;34(2):242-247.

[17] Tura BR, Martino HF, Gowdak LH,et al. Multicenter randomized trial of cell therapy in cardiopathies - MiHeart Study.Trials. 2007;8:2.

[18] Soares MB, Lima RS, Rocha LL,et al. Transplanted bone marrow cells repair heart tissue and reduce myocarditis in chronic chagasic mice. Am J Pathol. 2004;164(2):441-447.

[19] Schannwell CM. Stem cell therapy for cardiovascular diseases. Experiences in Düsseldorf. Dtsch Med Wochenschr. 2008;133 Suppl 8:S274-279.

[20] Psaltis PJ, Zannettino AC, Worthley SG,et al. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells. 2008;26(9):2201-2210.

[21] Boilson BA, Gulati R. Stem cell therapy for the heart: a perspective.Transl Res. 2010;155(1):3-5.

[22] Cranefield PF. Action potentials, afterpotentials, and arrhythmias. Circ Res. 1977;41(4):415-423.

[23] Valiunas V, Doronin S, Valiuniene L,et al. Human mesenchymal stem cells make cardiac connexins and form functional gap junctions. J Physiol. 2004;555(Pt 3):617-626.

[24] Leobon B, Garcin I, Menasche P,et al. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci U S A. 2003;100(13): 7808-7811.

[25] Price MJ, Chou CC, Frantzen M,et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol. 2006; 111(2):231-239.